论文部分内容阅读
据媒体报道,5月27日上午,中国科学院院士、国内著名病毒学家田波宣布,中科院微生物研究所、武汉大学现代病毒学研究中心经过一个半月的联合攻关,找到能够抑制SARS病毒与细胞融合的多肽,有望开发出抗击SARS病毒的特效药。 田波说“SARS病毒是一种囊膜病毒,通过囊膜融合蛋白和细胞膜的受体结合而侵入细胞。利用竞争抑制的原理,我们可以抢先占据SARS病毒囊膜融合蛋白的融合位点,使之失去和人体细胞融合的位置。”
According to media reports, on the morning of May 27, Chinese Academy of Sciences and domestic famous virologist Tian Bo announced that the Chinese Academy of Sciences Institute of Microbiology and Modern Virology Research Center of Wuhan University, after one and a half months of joint research, found to be able to inhibit SARS virus and cell fusion Peptides, is expected to develop a special drug against the SARS virus. Tian said that “the SARS virus is a glycoprotein that invades cells through the binding of the envelope fusion protein to the receptor of the cell membrane. Using the principle of competitive inhibition, we can preempt the fusion site of the SARS viral envelope fusion protein Lost and integration of human cells. ”